Naftifine

Summary

Naftifine (CHEMBL626) is an approved small-molecule EC 1.14.13.132 (squalene monooxygenase) inhibitor (ATC D01AE22); indicated across 2 conditions including tinea pedis and tinea unguium.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AE22
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 287.4 Da · C21H21N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL626
Name	Naftifine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	47641
ChEBI	CHEBI:7451
ATC	D01AE22
Molecular formula	C21H21N
Molecular weight	287.4
InChIKey	OZGNYLLQHRPOBR-DHZHZOJOSA-N

SMILES: CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C32

IUPAC name: (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine

ChEBI definition: A tertiary amine in which the nitrogen is substituted by methyl, α-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections.

Pharmacological roles (ChEBI): EC 1.14.13.132 (squalene monooxygenase) inhibitor, sterol biosynthesis inhibitor.

Also known as: Naft-500, Naftifina, Naftifine, naftifine, NAFTIFINE

Parent form; salt/anhydrous children: CHEMBL1200493

Patent coverage: 4,705 distinct patent families (16,569 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 16,396 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: Squalene epoxidase ERG1, Alpha-2C adrenergic receptor, D(2) dopamine receptor, Cannabinoid receptor 1, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Kappa-type opioid receptor, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P32352	6.51	Ki	310	nM	CHEMBL_ACT_1483977
Q92206	6.5	IC50	317	nM	CHEMBL_ACT_24835654
SIGMAR1	6.06	Ki	880	nM	CHEMBL_ACT_1483976
EBP	5.82	Ki	1500	nM	CHEMBL_ACT_1483975
KCNH2	5.69	AC50	2021	nM	CHEMBL_ACT_25117333
ADRA1A	5.67	AC50	2149	nM	CHEMBL_ACT_25137721
HTR2A	5.62	AC50	2395	nM	CHEMBL_ACT_25173488
DRD2	5.41	AC50	3900	nM	CHEMBL_ACT_25139977
ADRA2C	5.32	AC50	4800	nM	CHEMBL_ACT_25147520
CNR1	5.01	AC50	9865	nM	CHEMBL_ACT_25181422

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tinea pedis	3	MONDO:0005984	EFO:0007512
tinea unguium	2	MONDO:0001628	MONDO:0001628

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00750139	PHASE3	COMPLETED	Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
NCT00750152	PHASE3	COMPLETED	Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
NCT02633813	PHASE3	COMPLETED	BE Study of Naftifine HCL
NCT02658292	PHASE2	WITHDRAWN	Safety and Efficacy of NAFT900 in Children With Tinea Capitis
NCT01580891	PHASE1	COMPLETED	Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
NCT02132260	PHASE1	COMPLETED	Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis
NCT02335255	PHASE1	COMPLETED	Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).